(202) 599-8435

CLAAD Urges FDA To Phase Out Certain Non-Abuse-Deterrent Opioid Analgesics

On Monday, the Center for Lawful Access and Abuse Deterrence (CLAAD) submitted a citizen petition urging the FDA to phase out oral prescription opioid analgesics that lack abuse-deterrent properties after three oral abuse-deterrent opioids with the same active ingredient and release speed have been approved. CLAAD’s petition notes that the wide availability of traditional opioid analgesics has hindered the uptake of abuse-deterrent opioids. CLAAD’s approach to discontinuing traditional opioids accounts for the need for competition to address potential access and pricing concerns. Read more here.

Print Friendly
About the Author